Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Erika L. Nurmi is active.

Publication


Featured researches published by Erika L. Nurmi.


Translational Psychiatry | 2013

Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies

Erika L. Nurmi; S L Spilman; Fiona J. Whelan; L L Scahill; Michael G. Aman; Christopher J. McDougle; L E Arnold; Benjamin L. Handen; Cynthia R. Johnson; Denis G. Sukhodolsky; David J. Posey; Luc Lecavalier; Kimberly A. Stigler; Louise Ritz; Elaine Tierney; Benedetto Vitiello; James T. McCracken

Second-generation antipsychotic exposure, in both children and adults, carries significant risk for excessive weight gain that varies widely across individuals. We queried common variation in key energy balance genes (FTO, MC4R, LEP, CNR1, FAAH) for their association with weight gain during the initial 8 weeks in the two NIMH Research Units on Pediatric Psychopharmacology Autism Network trials (N=225) of risperidone for treatment of irritability in children/adolescents aged 4–17 years with autism spectrum disorders. Variants in the cannabinoid receptor (CNR)-1 promoter (P=1.0 × 10−6), CNR1 (P=9.6 × 10−5) and the leptin (LEP) promoter (P=1.4 × 10−4) conferred robust-independent risks for weight gain. A model combining these three variants was highly significant (P=1.3 × 10−9) with a 0.85 effect size between lowest and highest risk groups. All results survived correction for multiple testing and were not dependent on dose, plasma level or ethnicity. We found no evidence for association with a reported functional variant in the endocannabinoid metabolic enzyme, fatty acid amide hydrolase, whereas body mass index-associated single-nucleotide polymorphisms in FTO and MC4R showed only trend associations. These data suggest a substantial genetic contribution of common variants in energy balance regulatory genes to individual antipsychotic-associated weight gain in children and adolescents, which supersedes findings from prior adult studies. The effects are robust enough to be detected after only 8 weeks and are more prominent in this largely treatment naive population. This study highlights compelling directions for further exploration of the pharmacogenetic basis of this concerning multifactorial adverse event.


Pharmacogenomics Journal | 2014

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders

James T. McCracken; K K Badashova; David J. Posey; Michael G. Aman; Larry Scahill; Elaine Tierney; L E Arnold; Benedetto Vitiello; Fiona J. Whelan; Shirley Chuang; Mark Davies; Bhavik Shah; Christopher J. McDougle; Erika L. Nurmi

Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs), however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in ASD, as in typically developing children with attention-deficit/hyperactivity disorder. Genotype data were available for 64 children with ASD and hyperactivity who were exposed to MPH during a 1-week safety/tolerability lead-in phase and 58 who went on to be randomized to placebo and three doses of MPH during a 4-week blinded, crossover study. Outcome measures included the Clinical Global Impression-Improvement (CGI-I) scale and the Aberrant Behavior Checklist (ABC-hyperactivity index). A total of 14 subjects discontinued the study because of MPH side effects. Subjects were genotyped for variants in DRD1–DRD5, ADRA2A, SLC6A3, SLC6A4, MAOA and MAOB, and COMT. Forty-nine percent of the sample met positive responder criteria. In this modest but relatively homogeneous sample, significant differences by DRD1 (P=0.006), ADRA2A (P<0.02), COMT (P<0.04), DRD3 (P<0.05), DRD4 (P<0.05), SLC6A3 (P<0.05) and SLC6A4 (P<0.05) genotypes were found for responders versus non-responders. Variants in DRD2 (P<0.001) and DRD3 (P<0.04) were associated with tolerability in the 14 subjects who discontinued the trial. For this first MPH pharmacogenetic study in children with ASD, multiple monoaminergic gene variants may help explain individual differences in MPH’s efficacy and tolerability.


Molecular Psychiatry | 2016

Whole-genome association analysis of treatment response in obsessive-compulsive disorder.

Qin Hd; Samuels Jf; Youfa Wang; Zhu Y; Marco A. Grados; Mark A. Riddle; Benjamin D. Greenberg; James A. Knowles; Abby J. Fyer; James T. McCracken; Dennis L. Murphy; Steven A. Rasmussen; Bernadette Cullen; John Piacentini; Daniel A. Geller; Stewart Se; David L. Pauls; O. J. Bienvenu; Fernando S. Goes; Brady J. Maher; Ann E. Pulver; David Valle; Christoph Lange; Manuel Mattheisen; Nicole McLaughlin; Kung Yee Liang; Erika L. Nurmi; Askland Kd; G. Nestadt; Yin Yao Shugart

Up to 30% of patients with obsessive-compulsive disorder (OCD) exhibit an inadequate response to serotonin reuptake inhibitors (SRIs). To date, genetic predictors of OCD treatment response have not been systematically investigated using genome-wide association study (GWAS). To identify specific genetic variations potentially influencing SRI response, we conducted a GWAS study in 804 OCD patients with information on SRI response. SRI response was classified as ‘response’ (n=514) or ‘non-response’ (n=290), based on self-report. We used the more powerful Quasi-Likelihood Score Test (the MQLS test) to conduct a genome-wide association test correcting for relatedness, and then used an adjusted logistic model to evaluate the effect size of the variants in probands. The top single-nucleotide polymorphism (SNP) was rs17162912 (P=1.76 × 10−8), which is near the DISP1 gene on 1q41-q42, a microdeletion region implicated in neurological development. The other six SNPs showing suggestive evidence of association (P<10−5) were rs9303380, rs12437601, rs16988159, rs7676822, rs1911877 and rs723815. Among them, two SNPs in strong linkage disequilibrium, rs7676822 and rs1911877, located near the PCDH10 gene, gave P-values of 2.86 × 10−6 and 8.41 × 10−6, respectively. The other 35 variations with signals of potential significance (P<10−4) involve multiple genes expressed in the brain, including GRIN2B, PCDH10 and GPC6. Our enrichment analysis indicated suggestive roles of genes in the glutamatergic neurotransmission system (false discovery rate (FDR)=0.0097) and the serotonergic system (FDR=0.0213). Although the results presented may provide new insights into genetic mechanisms underlying treatment response in OCD, studies with larger sample sizes and detailed information on drug dosage and treatment duration are needed.


Child and Adolescent Psychiatric Clinics of North America | 2012

Genetics of Pediatric Anxiety Disorders

Dara Sakolsky; James T. McCracken; Erika L. Nurmi

This article reviews the familiality, linkage, candidate gene, and genomewide association studies of obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, and other anxiety disorders (ie, generalized anxiety disorder, separation anxiety disorder, social phobia, and specific phobia). Studies involving children and adolescents are highlighted. Clinical and research implications are discussed.


Pharmacogenomics Journal | 2016

Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample

Eva J. Brandl; Arun K. Tiwari; Clement C. Zai; Erika L. Nurmi; Nabilah I. Chowdhury; Tamara Arenovich; M Sanches; Vanessa F. Gonçalves; J J Shen; J.A. Lieberman; Herbert Y. Meltzer; J.L. Kennedy; Daniel J. Müller

Antipsychotic-induced weight gain (AIWG) is a common side effect with a high genetic contribution. We reanalyzed genome-wide association study (GWAS) data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) selecting a refined subset of patients most suitable for AIWG studies. The final GWAS was conducted in N=189 individuals. The top polymorphisms were analyzed in a second cohort of N=86 patients. None of the single-nucleotide polymorphisms was significant at the genome-wide threshold of 5x10−8. We observed interesting trends for rs9346455 (P=6.49x10−6) upstream of OGFRL1, the intergenic variants rs7336345 (P=1.31 × 10−5) and rs1012650 (P=1.47 × 10−5), and rs1059778 (P=1.49x10−5) in IBA57. In the second cohort, rs9346455 showed significant association with AIWG (P=0.005). The combined meta-analysis P-value for rs9346455 was 1.09 × 10−7. Our reanalysis of the CATIE GWAS data revealed interesting new variants associated with AIWG. As the functional relevance of these polymorphisms is yet to be determined, further studies are needed.The Pharmacogenomics Journal advance online publication, 1 September 2015; doi:10.1038/tpj.2015.59


Behavioural Brain Research | 2017

Interactive effects of attachment and FKBP5 genotype on school-aged children's emotion regulation and depressive symptoms.

Jessica L. Borelli; Patricia A. Smiley; Hannah F. Rasmussen; Anthony Gómez; Lauren C. Seaman; Erika L. Nurmi

Graphical abstract Figure. No caption available. HighlightsFKBP5 and attachment insecurity are associated with emotion dysregulation and depression.We examine their interaction in predicting outcomes in community sample of children.Parental overcontrol only associated with attachment insecurity among minor allele carriers.Genes and children’s insecurity interactively predict children’s dysregulation and depressive symptoms.Results generally support a differential susceptibility perspective. Abstract Attachment insecurity is influenced by both environmental and genetic factors, but few studies have examined the effects of gene‐environment interactions. In the context of environmental stress, a functional variant in the glucocorticoid receptor co‐chaperone FKBP5 gene has been repeatedly shown to increase risk for psychiatric illness, including depression. We expand on prior work by exploring cross‐sectional attachment by gene effects on both attachment insecurity and downstream physiological and behavioral measures in a diverse community sample of school‐aged children (N = 99, 49% girls, Mage = 10.29 years, 66.6% non‐White) and their mothers. Specifically, we examined moderating effects of FKBP5 rs3800373 genotype on the links between parenting insensitivity (overcontrol) and child attachment. Further, we assessed whether FKBP5 moderates the links between maternal and child attachment and children’s emotion regulation self‐report, respiratory sinus arrhythmia (RSA) in response to a standardized laboratory stressor, and depressive symptoms. Higher levels of overcontrol predicted lower child attachment security only in FKBP5 minor allele carriers. Among children with two minor alleles (CC), attachment security was negatively associated with emotion suppression, rumination, depressive symptoms, and RSA reactivity; similarly, for these children, maternal attachment anxiety was positively associated with depressive symptoms. The findings can be conceptualized in a differential susceptibility framework, where the FKBP5 minor allele confers either risk or resilience, depending on the parenting environment.


Pharmacogenomics | 2015

Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes

Jennie G. Pouget; Vanessa F. Gonçalves; Erika L. Nurmi; Christopher P Laughlin; Karyn S Mallya; James T. McCracken; Michael G. Aman; Christopher J. McDougle; Lawrence Scahill; Virginia L. Misener; Arun K. Tiwari; Clement C. Zai; Eva J. Brandl; Daniel Felsky; Amy Q Leung; Jeffrey A. Lieberman; Herbert Y. Meltzer; Steven G. Potkin; Charlotte Niedling; Werner Steimer; Stefan Leucht; Jo Knight; Daniel J. Müller; James L. Kennedy

AIM TSPO is a neuroinflammatory biomarker and emerging therapeutic target in psychiatric disorders. We evaluated whether TSPO polymorphisms contribute to interindividual variability in schizophrenia, antipsychotic efficacy and antipsychotic-induced weight gain. PATIENTS & METHODS We analyzed TSPO polymorphisms in 670 schizophrenia cases and 775 healthy controls. Gene-gene interactions between TSPO and other mitochondrial membrane protein-encoding genes (VDAC1 and ANT1) were explored. Positive findings were evaluated in two independent samples (Munich, n = 300; RUPP, n = 119). RESULTS TSPO rs6971 was independently associated with antipsychotic-induced weight gain in the discovery (puncor = 0.04) and RUPP samples (p = 3.00 × 10(-3)), and interacted with ANT1 rs10024068 in the discovery (p = 1.15 × 10(-3)) and RUPP samples (p = 2.76 × 10(-4)). CONCLUSION Our findings highlight TSPO as a candidate for future investigations of antipsychotic-induced weight gain, and support the involvement of mitochondrial membrane components in this serious treatment side effect.


European Neuropsychopharmacology | 2017

Polygenic risk score and heritability estimates reveals a genetic relationship between ASD and OCD.

Wei Guo; Jack Samuels; Ying Wang; H. Cao; McKenzie Ritter; Paul S. Nestadt; Janice Krasnow; Benjamin D. Greenberg; Abby J. Fyer; James T. McCracken; Daniel A. Geller; Dennis L. Murphy; James A. Knowles; Marco A. Grados; Mark A. Riddle; Steven A. Rasmussen; Nicole McLaughlin; Erika L. Nurmi; Askland Kd; Bernadette Cullen; John Piacentini; David L. Pauls; O. J. Bienvenu; Stewart Se; Fernando S. Goes; Brady J. Maher; Ann E. Pulver; David Valle; Manuel Mattheisen; Ji Qian

Obsessive-compulsive disorder (OCD) and Autism spectrum disorder (ASD) are both highly heritable neurodevelopmental disorders that conceivably share genetic risk factors. However, the underlying genetic determinants remain largely unknown. In this work, the authors describe a combined genome-wide association study (GWAS) of ASD and OCD. The OCD dataset includes 2998 individuals in nuclear families. The ASD dataset includes 6898 individuals in case-parents trios. GWAS summary statistics were examined for potential enrichment of functional variants associated with gene expression levels in brain regions. The top ranked SNP is rs4785741 (chromosome 16) with P value=6.9×10-7 in our re-analysis. Polygenic risk score analyses were conducted to investigate the genetic relationship within and across the two disorders. These analyses identified a significant polygenic component of ASD, predicting 0.11% of the phenotypic variance in an independent OCD data set. In addition, we examined the genomic architecture of ASD and OCD by estimating heritability on different chromosomes and different allele frequencies, analyzing genome-wide common variant data by using the Genome-wide Complex Trait Analysis (GCTA) program. The estimated global heritability of OCD is 0.427 (se=0.093) and 0.174 (se=0.053) for ASD in these imputed data.


American Journal of Psychiatry | 2017

Cortical Abnormalities Associated with Pediatric and Adult Obsessive-Compulsive Disorder: Findings from the Enigma Obsessive-Compulsive Disorder Working Group

Premika S.W. Boedhoe; Lianne Schmaal; Paul D. Arnold; Francesco Benedetti; Jan C. Beucke; Yuqi Cheng; Damiaan Denys; Katherine A. Fitzgerald; Patricia Gruner; Marcelo Q. Hoexter; Chaim Huyser; Anthony A. James; Kathrin Koch; Jun Soo Kwon; Luisa Lazaro; David Mataix-Cols; José M. Menchón; Takashi Nakamae; Tomohiro Nakao; Erika L. Nurmi; Y.C. Janardhan Reddy; H. Blair Simpson; Noam Soreni; Gianfranco Spalletta; David F. Tolin; Susanne Walitza; Zhen Wang; Paul M. Thompson; Dan J. Stein; Odile A. van den Heuvel

OBJECTIVE Brain imaging studies of structural abnormalities in OCD have yielded inconsistent results, partly because of limited statistical power, clinical heterogeneity, and methodological differences. The authors conducted meta- and mega-analyses comprising the largest study of cortical morphometry in OCD ever undertaken. METHOD T1-weighted MRI scans of 1,905 OCD patients and 1,760 healthy controls from 27 sites worldwide were processed locally using FreeSurfer to assess cortical thickness and surface area. Effect sizes for differences between patients and controls, and associations with clinical characteristics, were calculated using linear regression models controlling for age, sex, site, and intracranial volume. RESULTS In adult OCD patients versus controls, we found a significantly lower surface area for the transverse temporal cortex and a thinner inferior parietal cortex. Medicated adult OCD patients also showed thinner cortices throughout the brain. In pediatric OCD patients compared with controls, we found significantly thinner inferior and superior parietal cortices, but none of the regions analyzed showed significant differences in surface area. However, medicated pediatric OCD patients had lower surface area in frontal regions. Cohens d effect sizes varied from -0.10 to -0.33. CONCLUSIONS The parietal cortex was consistently implicated in both adults and children with OCD. More widespread cortical thickness abnormalities were found in medicated adult OCD patients, and more pronounced surface area deficits (mainly in frontal regions) were found in medicated pediatric OCD patients. These cortical measures represent distinct morphological features and may be differentially affected during different stages of development and illness, and possibly moderated by disease profile and medication.


Frontiers in Molecular Neuroscience | 2017

Genome Wide Association Study (GWAS) between Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive Compulsive Disorder (OCD)

McKenzie Ritter; Wei Guo; Jack Samuels; Ying Wang; Paul S. Nestadt; Janice Krasnow; Benjamin D. Greenberg; Abby J. Fyer; James T. McCracken; Daniel A. Geller; Dennis L. Murphy; James A. Knowles; Marco A. Grados; Mark A. Riddle; Steven A. Rasmussen; Nicole McLaughlin; Erika L. Nurmi; Kathleen D. Askland; Bernadette Cullen; John Piacentini; David L. Pauls; Joseph Bienvenu; Evelyn Stewart; Fernando S. Goes; Brion S. Maher; Ann E. Pulver; Manuel Mattheisen; Ji Qian; Gerald Nestadt; Yin Yao Shugart

Objective: The aim of this study was to identify any potential genetic overlap between attention deficit hyperactivity disorder (ADHD) and obsessive compulsive disorder (OCD). We hypothesized that since these disorders share a sub-phenotype, they may share common risk alleles. In this manuscript, we report the overlap found between these two disorders. Methods: A meta-analysis was conducted between ADHD and OCD, and polygenic risk scores (PRS) were calculated for both disorders. In addition, a protein-protein analysis was completed in order to examine the interactions between proteins; p-values for the protein-protein interaction analysis was calculated using permutation. Conclusion: None of the single nucleotide polymorphisms (SNPs) reached genome wide significance and there was little evidence of genetic overlap between ADHD and OCD.

Collaboration


Dive into the Erika L. Nurmi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ann E. Pulver

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dennis L. Murphy

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

James A. Knowles

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Marco A. Grados

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Mark A. Riddle

Johns Hopkins University School of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge